PLX | Protalix BioTherapeutics, Inc. Stock Overview

(Stock Exchange: AMEX)

Day's Range	N/A - N/A
52 Week Range	N/A - N/A
Beta	0.10
Implied Volatility	208.59%
IV Rank	16.52%
Day's Volume	N/A
Average Volume	N/A
Shares Outstanding	N/A
Market Cap	N/A
Sector	Healthcare
Industry	Biotechnology
IPO Date	1998-05-15

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	-1.59
EPS	N/A
1YR Price Target	9.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	208
Country	USA
Website	PLX

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa, for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. Its pipeline products include Alidornase Alfa, Pegunigalsidase Alfa, and Oprx-106. The company's primary sources of revenues include its sales of taliglucerase alfa in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement.

PLX's peers: ADMA, AKBA, BCLI, BLRX, BYSI, CANF, DARE, ENLV, EVGN, EYPT, IBRX, IFRX, INVA, ORMP, OTLK, CRVS, ALDX, GMDA, CKPT, CDTX, XFOR, MCRB, EFTR, PDSB, LIFE, ELEV, LXRX, IOVA, IMGN, RVPH, SLS, VERU, VRCA, XERS

*Chart delayed

Analyzing fundamentals for PLX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is good and Health is frighteningly weak. For more detailed analysis please see PLX Fundamentals page.

Watching at PLX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on PLX Technicals page.